Gelonghui, April 26 | Erkang Pharmaceutical (300267.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 276 million yuan, down 49.57% year on year; net profit attributable to shareholders of listed companies was 2.9015 million yuan, down 88.87% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 3.3425 million; basic earnings per share.
尔康制药(300267.SZ)：一季度净利润290.15万元 同比下降88.87%
Erkang Pharmaceutical (300267.SZ): Net profit of 2.9015 million yuan in the first quarter decreased by 88.87% year on year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.